阿尔茨海默病(AD)是一种进行性脑部疾病,也是痴呆和健忘症最常见的原因之一。由于AD发病机制复杂,潜在机制尚不清楚.尽管科学家们在开发治疗AD的药物方面做出了越来越多的努力,没有发现有效的治疗药物。
天然产物及其成分已显示出治疗神经退行性疾病的前景,包括AD。因此,深入研究药用植物,及其抗AD的主要活性成分,是设计治疗剂所必需的。
在这项研究中,N2a/APP细胞和SAMP8小鼠用作AD的体外和体内模型。使用多种分子生物学方法来研究石竹A的潜在治疗作用,以及潜在的机制。
结果表明,石竹A,一种新的化合物,从山竹中提取,能降低淀粉样前体蛋白(APP)和淀粉样β(Aβ)蛋白的表达水平,并减轻SAMP8小鼠的认知功能下降。对潜在机制的进一步研究表明,石竹A通过Akt-GSK3β和Nrf2-Keap1-HO-1途径发挥抗氧化作用。Conclusions.一起来看,我们的研究结果为AD治疗药物的发现提供了新的视野.
Alzheimer\'s disease (AD) is a progressive brain disorder, and one of the most common causes of dementia and amnesia. Due to the complex pathogenesis of AD, the underlying mechanisms remain unclear. Although scientists have made increasing efforts to develop drugs for AD, no effective therapeutic agents have been found.
Natural products and their constituents have shown promise for treating neurodegenerative diseases, including AD. Thus, in-depth study of medical plants, and the main active ingredients thereof against AD, is necessary to devise therapeutic agents.
In this study, N2a/APP cells and SAMP8 mice were employed as in vitro and in vivo models of AD. Multiple molecular biological methods were used to investigate the potential therapeutic actions of oxyphylla A, and the underlying mechanisms.
Results showed that oxyphylla A, a novel compound extracted from Alpinia oxyphylla, could reduce the expression levels of amyloid precursor protein (APP) and amyloid beta (Aβ) proteins, and attenuate cognitive decline in SAMP8 mice. Further investigation of the underlying mechanisms showed that oxyphylla A exerted an antioxidative effect through the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways.Conclusions.Taken together, our results suggest a new horizon for the discovery of therapeutic agents for AD.